Zheng Quan Zhi Xing·2025-08-26 16:23Fundraising Overview - The total amount raised through the non-public offering was RMB 448,378 million, with a net amount of RMB 445,619.87 million after deducting issuance costs [1] - As of June 30, 2025, RMB 12,166.07 million of the raised funds had been utilized, leaving a balance of RMB 9,477.74 million [2][4] - The remaining balance includes RMB 7,605.99 million temporarily used to supplement working capital, while RMB 2,307.66 million is in the special account [2][4] Fund Management - The company has established a fundraising management system to regulate the storage, use, and supervision of the raised funds [2] - Special accounts for the raised funds have been opened with commercial banks, and a tripartite supervision agreement has been signed with the sponsor and banks [3] Fund Utilization - The actual use of the raised funds during the reporting period was RMB 12,166.07 million, with no instances of replacing the funds [4][8] - As of June 30, 2025, RMB 7,605.99 million of the temporarily supplemented working capital had been returned by July 7, 2025 [5][9] Changes in Fund Investment Projects - The company approved adjustments to the investment amounts for certain projects to enhance the efficiency of fund usage, including reallocating RMB 19,314 million to a new project related to innovative drug clinical trials [6][10] - New sub-projects have been added, with specific reallocations including reductions for "Balixafortide" and "COVID-19 mRNA vaccine" projects, and increases for "FS-1502," "FCN-338," and "SAF-189" projects [6][9] Compliance and Disclosure - The company has complied with relevant regulations regarding the use and disclosure of raised funds, ensuring timely and accurate reporting [6][7]